A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Seagen Inc.
University of Colorado, Denver
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
Eisai Inc.
Acrotech Biopharma Inc.
Chipscreen Biosciences, Ltd.
University of Aarhus
Lymphoma Study Association
Yale University
M.D. Anderson Cancer Center